These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19493342)

  • 1. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.
    McRonald FE; Morris MR; Gentle D; Winchester L; Baban D; Ragoussis J; Clarke NW; Brown MD; Kishida T; Yao M; Latif F; Maher ER
    Mol Cancer; 2009 Jun; 8():31. PubMed ID: 19493342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
    Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
    PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic changes in the origin and development of renal cell carcinoma (RCC).
    Glavac D; Ravnik-Glavac M; Ovcak Z; Masera A
    Pflugers Arch; 1996; 431(6 Suppl 2):R193-4. PubMed ID: 8739330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic alterations during renal carcinogenesis.
    Arai E; Kanai Y
    Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
    Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
    Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
    Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
    Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
    Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T
    J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
    Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
    Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker.
    de Martino M; Klatte T; Haitel A; Marberger M
    Cancer; 2012 Jan; 118(1):82-90. PubMed ID: 21713763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.
    Oh RR; Park JY; Lee JH; Shin MS; Kim HS; Lee SK; Kim YS; Lee SH; Lee SN; Yang YM; Yoo NJ; Lee JY; Park WS
    APMIS; 2002 Mar; 110(3):229-38. PubMed ID: 12076276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
    Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
    Batavia AA; Schraml P; Moch H
    Histopathology; 2019 Jan; 74(1):60-67. PubMed ID: 30565303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.